CGP testing was performed using hybrid capture-based targeted DNA sequencing with FoundationOne CDx (Foundation Medicine), the OncoGuide NCC Oncopanel System (Sysmex Corporation), in-house NGS testing, or in blood-derived cell-free DNA with FoundationOne Liquid CDx (Foundation Medicine) or Guardant360 CDx (Guardant Health).4 (link),25 (link),26 (link),27 (link) All patients were referred to the NCCH following discussion by regional molecular tumor boards (MTB) comprising medical oncologists, pediatric oncologists, pathologists, bioinformaticians, genome researchers, and genetic counselors.3 (link),28 (link) In addition to reports from the inspection companies, the MTBs used reports containing clinical annotation and information regarding genotype-matched clinical trials from the Center for Cancer Genomics and Advanced Therapeutics national database.29 (link),30 (link)
Free full text: Click here